Biotech Values

[bladerunner1717]

Dew,

How does TocP compare to Abraxane? Doesn't TocP have some advantages over Abraxane? PGS, how do you account for the success of Abraxane? Abraxane seems to have done ok in the marketplace. $134 million in its first year. ABBI has a market cap of over $3.5 billion.

"Under the terms of the agreement, AstraZeneca will pay $200m to Abraxis BioScience for the right to co-promote ABRAXANE within the U.S. The co-promotion is for an initial five and a half year term, beginning on July 1st, 2006. During the co-promotion term, AstraZeneca will dedicate sales representatives to support ABRAXANE and will fund half of the spend for the promotional and advertising programme. Further milestone payments will be made to Abraxis upon the achievement of new indication approvals within pre-specified timelines. AstraZeneca will be paid a commission of 22 per cent of ABRAXANE net sales within the U.S. during this term, with a trailing commission of 10 per cent and 5 per cent for the two years following the end of this period. Abraxis BioScience will also grant AstraZeneca right of first refusal to license or co-promote ABRAXANE outside the U.S., other than selected countries, should a partner be sought. In 2005, Abraxis BioScience recorded $134m of ABRAXANE sales within the U.S. in its first year of launch."


Bladerunner